Johnson & Johnson (NYSE:JNJ) & UBS Group AG (USA) (NYSE:UBS) News Recap

Amos Gonzales
May 18, 2017

Johnson & Johnson (NYSE:JNJ) traded down 0.35% on Thursday, reaching $123.51. Johnson & Johnson now has $353.52B valuation. The stock increased 0.61% or $0.78 on May 16, reaching $127.77.

Marchex, a mobile advertising analytics company. The relative volume of the stock is 1.15, while its market cap is $343.71 Billion. The Firm offers services and products for enterprises that depend on consumer phone calls to drive sales. It now has negative earnings. The institutional investor held 15,573 shares of the major pharmaceuticals company at the end of 2017Q1, valued at $1.94 million, down from 110,964 at the end of the previous reported quarter. JNJ's profit will be $4.92 billion for 17.84 P/E if the $1.78 EPS becomes a reality. Comparatively, Johnson & Johnson posted earnings of $1.78 per share in the same quarter past year. Johnson & Johnson earned a daily sentiment score of 0.37 on AlphaOne's scale. Its up 0.12, from 0.82 in 2016Q3.

Kentucky Retirement Systems bought a new position in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, Holdings Channel reports. Stock investors acquired 3,075 call options on the company. Hancock Holdg Co reported 132,979 shares or 0.57% of all its holdings. Roffman Miller Assocs Pa, a Pennsylvania-based fund reported 190,263 shares. Johnson & Johnson (NYSE:JNJ) has risen 6.00% since April 17, 2017 and is uptrending. The stock witnessed 1.6% gains, 10.31% gains and 7.67% gains for the 1-month, 3-month and 6-month period, respectively. The 1832 Asset Management Lp holds 4.35 million shares with $382.62 million value, up from 2.59M last quarter. Ancora Advsrs Limited Liability Co has invested 0.9% of its portfolio in Johnson & Johnson (NYSE:JNJ). Lvm Capital Management Mi reported 114,288 shares stake. Condor Cap Management owns 120,882 shares. Ingalls Snyder Lc has invested 1.16% in Johnson & Johnson (NYSE:JNJ). Dubuque Natl Bank And Tru Co holds 44,760 shares. New Vernon Mgmt Ltd Liability invested 0.87% in Johnson & Johnson (NYSE:JNJ).

Since February 1, 2017, it had 0 insider buys, and 5 selling transactions for $14.98 million activity. The company has total market capitalization of $227.42B and a total of 3.74B outstanding shares. $2.58M worth of Johnson & Johnson (NYSE:JNJ) was sold by Stoffels Paulus on Wednesday, February 15. Bragg Fincl stated it has 1.32% of its portfolio in Johnson & Johnson (NYSE:JNJ). Another trade for 21,735 shares valued at $2.45M was made by Ullmann Michael H on Wednesday, February 1. $1.78M worth of Johnson & Johnson (NYSE:JNJ) was sold by Kapusta Ronald A. Therefore 43% are positive. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $129.00. $116.40's average target is -8.90% below currents $127.77 stock price. Analysts expect that Johnson & Johnson will post $7.10 EPS for the current fiscal year.

GOP, Dems and even Trump welcome special counsel appointment
Amash is a member of the hardline House Freedom Caucus who has already has called for an independent commission to investigate. The move followed a week in which the White House was thrown into uproar after Trump fired FBI Director James Comey.

The target price for Johnson & Johnson (JNJ) is $129/share according to the consensus of analysts working on the stock, with an expected EPS of $1.78/share for the current quarter.

Institutional investors now hold around $242.69 billion or 68.7% in JNJ stock. The rating was maintained by Argus Research on Wednesday, April 20 with "Buy". The firm has "Overweight" rating given on Monday, May 15 by JP Morgan. The firm earned "Equal-Weight" rating on Tuesday, November 29 by Barclays Capital. UBS has "Buy" rating and $144.0 target. The stock has "Neutral" rating by Goldman Sachs on Monday, March 14. As per Wednesday, January 25, the company rating was maintained by RBC Capital Markets. Stock has got OUTPERFORM rating from 4 analysts of Thomson Reuters, 13 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the company. The lowest target is $5 while the high is $9. Price Target plays a critical role when it comes to the analysis of a Stock. Blucora had 8 analyst reports since August 22, 2015 according to SRatingsIntel. Piper Jaffray maintained Marchex, Inc. Atlantic Securities initiated Johnson & Johnson (NYSE:JNJ) on Friday, December 18 with "Neutral" rating.

The case, filed in a NY state court on Thursday, is the latest lawsuit by local and state governments seeking to hold drugmakers accountable for a national opioid epidemic. As per Monday, August 24, the company rating was maintained by Benchmark. Wealthtrust Axiom Lc owns 15,484 shares or 0.65% of their U.S. portfolio. Meristem Limited Liability Partnership, Minnesota-based fund reported 32,461 shares. Family Management holds 3,601 shares or 0.28% of its portfolio. About shares traded. Marchex, Inc. It is down 6.00% since April 16, 2017 and is uptrending.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by BadHub

Discuss This Article